San Francisco, CA, United States of America

Son Minh Pham

USPTO Granted Patents = 25 (Patent Applications = 30)

EPO Patents = 2 (Patent Applications = 32)

Average Co-Inventor Count = 7.4

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

Medivation Technologies, Inc.

Years Active: 2017-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398121 - Anti-cancer nuclear hormone receptor-targeting compounds (2025-08-26),

2. 12208141 - Anti-cancer nuclear hormone receptor-targeting compounds (2025-01-28),

3. 12006314 - Anti-cancer nuclear hormone receptor-targeting compounds (2024-06-11),

4. 11952349 - Anti-cancer nuclear hormone receptor-targeting compounds (2024-04-09),

5. 11834458 - Anti-cancer nuclear hormone receptor-targeting compounds (2023-12-05),

6. 11826430 - Anti-cancer nuclear hormone receptor-targeting compounds (2023-11-28),

7. 11702401 - Compounds and methods of use (2023-07-18),

8. 11584756 - Heterocyclic compounds as BET inhibitors (2023-02-21),

9. 11485725 - Derivatives of piperlongumine and uses thereof (2022-11-01),

10. 11332473 - Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors (2022-05-17),

11. 11306071 - Heterocyclic compounds as adenosine antagonists (2022-04-19),

12. 11299493 - Heterocyclic compounds and uses thereof (2022-04-12),

13. 11292782 - Diarylhydantoin compounds and methods of use thereof (2022-04-05),

14. 11254670 - 1,8-naphthyridinone compounds and uses thereof (2022-02-22),

15. 11192900 - Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors (2021-12-07),

Title: The Innovative Contributions of Son Minh Pham in Cancer Research

Introduction: Son Minh Pham, based in San Francisco, CA, is a prominent inventor recognized for his significant contributions to cancer research. With an impressive portfolio of 24 patents, his work focuses on developing novel anti-cancer compounds derived from nuclear hormone receptor binders. His innovative approach seeks to enhance therapeutic options for cancer treatment.

Latest Patents: Son Minh Pham's latest patents demonstrate his commitment to advancing cancer therapeutics. His disclosures include anti-cancer nuclear hormone receptor-targeting compounds. These compounds are derived from nuclear steroid receptor binders and include a variety of formulations such as tautomers, stereoisomers, and pharmaceutically acceptable salts. Each patent aims to provide valuable insights into methods for their use and preparation, catering to the pressing need for effective cancer treatments.

Career Highlights: Throughout his career, Son Minh Pham has made substantial contributions in the pharmaceutical sector. He has worked with notable companies, including Nuvation Bio Inc. and Medivation Technologies, Inc. His dedication to innovation has established him as a leading figure in the field of cancer research.

Collaborations: Collaboration has been a key aspect of Son Minh Pham's career. He has worked alongside talented individuals such as Sarvajit Chakravarty and Jayakanth Kankanala. These partnerships have fostered an environment of creativity and shared expertise, paving the way for groundbreaking advancements in the fight against cancer.

Conclusion: In conclusion, Son Minh Pham is a distinguished inventor whose work has profound implications for cancer treatment. With 24 patents to his name, his contributions through anti-cancer nuclear hormone receptor-targeting compounds exemplify his pioneering spirit. As he continues his innovative journey, his research stands to benefit countless individuals battling cancer worldwide.

This text is generated by artificial intelligence and may not be accurate.